Castleman disease of the pancreas mimicking pancreatic malignancy on $^{68}$Ga-DOTATATE and $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report

Liu SL et al. Castleman disease of the pancreas

Sheng-Lu Liu, Ming Luo, Hao-Xian Gou, Xiao-Li Yang, Kai He

Abstract

BACKGROUND
Castleman disease is an uncommon nonclonal lymphoproliferative disorder, which frequently mimics both benign and malignant abnormalities in multiple body parts. Depending on the number of lymph nodes or regions involved, Castleman disease varies in diagnosis, treatment, and prognosis. It rarely occurs in the pancreas alone without any distinct clinical feature and tends to be confused with pancreatic paraganglioma (PGL), neuroendocrine tumors (NETs), and primary tumors, thus impeding proper diagnosis and treatment.

CASE SUMMARY
A 28-year-old woman presented with a lesion on the neck of the pancreas, detected by ultrasound during health examination. Physical examination and laboratory findings were normal. The mass showed hypervascularity on enhanced computed tomography (CT), significantly increased $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) uptake on FDG positron emission tomography (PET)/CT, and slightly increased somatostatin receptor (SSTR) expression on $^{68}$Ga-DOTATATE PET/CT, suggesting no distant metastases and
subdiagnoses such as pancreatic PGL, NET, or primary tumor. Intraoperative pathology suggested lymphatic hyperplasia, and only simple tumor resection was performed. The patient was diagnosed with the hyaline vascular variant of Castleman disease, which was confirmed by postoperative immunohistochemistry. The patient was discharged successfully, and no recurrence was observed on regular review.

CONCLUSION
When PET/CT shows that the lesion is in the pancreas alone with no distant metastases, in addition to rich blood supply, high glucose uptake and slightly elevated SSTR expression are potentially new diagnostic features of Castleman disease of the pancreas, and the disease prognosis tends to improve.

Key Words: Castleman disease; Pancreatic malignancy; Pancreatic paraganglioma; Pancreatic neuroendocrine tumors; Positron emission tomography; Case report


Core Tip: Some rare tumors with high blood supply to the pancreas, such as Castleman disease, paraganglioma, and neuroendocrine tumors are difficult for clinicians to differentially diagnose based on conventional imaging and clinical presentation. In our case, Castleman disease of the pancreas had no obvious clinical features as previously reported but showed higher glucose uptake and mildly increased somatostatin receptor expression on positron emission tomography/computed tomography, which might help in the diagnosis.

INTRODUCTION
Castleman disease, a rare nonclonal lymphoproliferative disorder of unknown etiology, is alternatively known as giant lymph node hyperplasia or angiofollicular lymph node hyperplasia, first described by Dr. Benjamin Castleman in 1954. Variably manifested and capable of influencing any region in the body, Castleman disease largely imitates both benign and malignant tumors in the neck, thorax, abdomen, and pelvis. Despite increasing reports on Castleman disease, the condition remains difficult to diagnose, particularly when it appears as a pancreatic mass. With the ability to collect structural and metabolic information, $^{18}$fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}$FDG PET/CT) plays a pivotal role in the early diagnosis, robust characterization, and therapeutic evaluation of Castleman disease. However, no $^{18}$FDG PET/CT images of pancreatic Castleman disease have thus far been reported. $^{68}$Ga-DOTATATE PET/CT is the first choice for evaluating the well-differentiated histologic subtypes of neuroendocrine tumors (NETs), but its diagnostic value for identifying Castleman disease has yet to be determined.

CASE PRESENTATION

Chief complaints
A 28-year-old female presented to our department with the complaint of a pancreatic lesion, which was detected by ultrasound during a physical examination conducted 1 wk earlier.

History of present illness
The patient showed a feel-good self-report without abdominal pain, distension, diarrhea, fever, and other discomforts.

History of past illness
The patient had good health history.

Personal and family history
The personal and family history of the patient was unremarkable.

**Physical examination**
The vital signs of the patient were within the normal range. No yellow staining of skin and sclera was observed. Abdominal physical examination revealed no positive signs without tenderness and lumps in the abdomen.

**Laboratory examinations**
Blood analysis revealed mild anemia, with low hemoglobin concentration (102 g/L), normal leukocyte count, and normal platelet count. All liver function indexes were normal. The following were also normal: levels of serum amylase, lipase, and alkaline phosphatase; plasma or urinary metanephrine levels; and tumor markers for alpha-fetoprotein (AFP, 1.97 ng/mL), carcinoembryonic antigen (CEA, 3.63 ng/mL), carbohydrate antigen 153 (CA153, 16.40 U/mL), and carbohydrate antigen 199 (CA199, 19.66 U/mL). Endoscopic results suggested chronic non-atrophic gastritis with erosion. Fasting and postprandial insulin levels were within the normal range.

**Imaging examinations**
A plain CT scan (Figure 1A) showed a hyperdense lesion (arrow) measuring 3.0 cm × 2.0 cm × 2.5 cm in the neck of the pancreas. On contrast-enhanced CT, the lesion (arrow) showed significant enhancement in the arterial phase (Figure 1B), evenly distributed with smooth and well-defined boundaries, and gradually washed out in the venous phase (Figure 1C). ¹⁸F-FDG PET/CT images (Figure 2) showed glucose hypermetabolism with an standardized uptake value (SUV)$_{\text{max}}$ of 3.6 in the pancreatic mass. ⁶⁸Ga-DOTATATE PET/CT images (Figure 3) revealed minimally increased expression of somatostatin receptor (SSTR) on the pancreatic mass (arrows) with a SUV$_{\text{max}}$ of 5.8.

**FINAL DIAGNOSIS**
The final diagnosis of the presented case was pancreatic hypervascular malignancy, not excluding Castleman disease, paraganglioma (PGL), and NETs.

**TREATMENT**
On the basis of neoplastic etiology, we intended to perform pancreaticoduodenectomy. During exploratory laparotomy, we found that the mass had a rich blood supply. We completely separated it from the pancreatic tissue. The size of the tumor was 3.5 cm × 3 cm with a complete envelope (Figure 4A). Intraoperative frozen section examination (hematoxylin-eosin staining) suggested lymphatic hyperplasia, germinal centers with regressive transformation, and expanded mantle with “an onion skin” rimming of small lymphocytes (Figure 4B). Given the high probability of a benign mass, we performed simple tumor resection.

**OUTCOME AND FOLLOW-UP**
Immunohistochemistry: CD3 and CD5 (T zone +), CD20 (B zone +), CD10 and BCL-6 (germinal center +), BCL-2 (low expression in the germinal center, high expression outside the germinal center), CD21 (Figure 4C) and CD23 (follicular dendritic cell proliferation in the germinal center), Ki-67 (Figure 4D, high expression in the germinal center, low expression outside the germinal center), and Cyclin D1 (-). The immunohistochemical profile was consistent with the hyaline vascular variant of Castleman disease. The patient showed no apparent discomfort after surgery and was discharged after 1 wk. No recurrence of abdominal ultrasonography was reported after half a year.

**DISCUSSION**
Castleman disease occurs throughout the body. Approximately 70% of the condition presents in the chest, 15% in the neck, and 15% in the abdomen-pelvis, principally involving lymphoid tissues. Castleman disease also occasionally occurs in extralymphatic sites, such as the larynx, lungs, pancreas, meninges, and muscles[6-8]. It is
subclassified because of the number of enlarged lymph nodes\textsuperscript{[9]}. The involvement of a single lymph node or region is referred to as unicentric Castleman disease (UCD), whereas that of multiple lymph nodes is known as multicentric Castleman disease (MCD). A battery of pathologic variants includes the classic hyaline vascular type, the less common plasma cell variant and human herpesvirus 8-associated type, and the multicentric type, not otherwise specified\textsuperscript{[10]}. Moreover, 90% of the cases of hyaline vascular Castleman disease are unicentric\textsuperscript{[11]}. UCD typically manifests as an asymptomatic mass with a benign growth, but MCD presents with diffuse lymphadenopathy, organ dysfunction, and systemic inflammation.

Complete removal of lymph nodes is an effective and usually curative treatment for UCD, and the recurrence rate is extremely low. Chemotherapy and radiotherapy are alternative therapies when the mass cannot be completely removed surgically\textsuperscript{[9,12]}. By contrast, MCD has a poor prognosis, with a high recurrence rate associated with clinicopathological features and a high risk of malignancy leading to possible transformation into malignant lymphoma, plasmacytoma and Kaposi’s sarcoma, among others\textsuperscript{[6]}. Meanwhile, treatment options for multicenter Castleman disease are complex and include steroid therapy, chemotherapy, antiviral drugs, or the use of antiproliferative regimens\textsuperscript{[4,13]}. Therefore, the clinical typing of Castleman disease determines the corresponding diagnosis and prognosis.

Conventional imaging [CT/magnetic resonance imaging (MRI)] is not widely used to guide typing because it fails to distinguish clearly between reactive hyperplasia and pathological enlargement of lymph nodes, nor does it sensitively detect the involvement of normal-sized lymph nodes\textsuperscript{[4]}. However, \textsuperscript{18}FDG-PET/CT can be used to assess the metabolism of lymph node enlargement. Although lymph node biopsy is the only method for the definitive diagnosis of Castleman disease, available evidence suggests that previous FDG-PET/CT can help differentiate Castleman disease subtypes and guide subsequent treatment and monitoring\textsuperscript{[13]}. In our case, the \textsuperscript{18}FDG-PET/CT results showed that the mass was solitary in the pancreas with high glucose metabolism and no distant metastases, consistent with the diagnosis of UCD. Castleman disease is
rarely reported on $^{68}$Ga-DOTATATE PET/CT, and the ability and accuracy of its classification are unknown. In our case, UCD showed slightly higher SSTR expression.

When the tumor is located in the pancreas and is highly vascularized, some rare conditions other than Castleman's disease including PGL and NETs should also be considered.[14]

PGL, a rare type of vascular neuroendocrine tumor, results from a paraganglionic cell cluster that develops from the ectoderm of the neural crest[15]. The majority of the tumors are benign, and only 10% of the tumors are malignant. Although up to 77% of the tumors are commonly located retroperitoneally, the PGL is rarely located in the pancreas. A retrospective analysis of 15 cases diagnosed with PGL located in the pancreas summarized the clinical and imaging features of the disease[14]. Most patients exhibit no apparent symptoms or abdominal discomfort caused by compression. Enhanced CT suggests significant enhancement of the mass at the early stage. MRI images reveal tumor isointensity for the T1-weighted image and hyperintensity, hypointensity, or mixed intensity for the T2-weighted image. PGL located in the chest and pelvis may overproduce some hormones, particularly catecholamine which causes sweating, palpitations, and hypertension. PGLs most commonly overexpress SSTR2. $^{68}$Ga-Somatostatin agonists (SSTas) target SSTR2 and are internalized into the cells. DOTA-coupled SSTas exhibit excellent affinity for SSTR2[16]. Owing to its ultrahigh detection rate, $^{68}$Ga DOTA-somatostatin analog PET/CT has become the preferred imaging approach to diagnosing retroperitoneal PGL[17]. However, $^{68}$Ga SSTas PET can inevitably lead to false-positive findings, including metastatic lymph nodes owing to various cancers, menigioma, the pituitary gland, inflammatory diseases, and some rare conditions, such as fibrous dysplasia[18]. Focal pancreatic accumulation in the uncinate process may mimic pancreatic NETs.

Pancreatic NETs (pNETs) are heterogeneous epithelial neoplasms derived from pluripotent stem cells of the neuroendocrine system[19]. The tumor is malignant and classified as either functional or nonfunctional[14]. Nonfunctional pNETs are asymptomatic or manifest local compression, whereas functional pNETs cause clinical
syndromes associated with hormone hypersecretion according to the cell of origin. In MRI images, the tumor presents hypointensity on T1WI and mostly hyperintensity on T2WI; however, few are isointense or hypointense. In enhanced CT images, the functional pNET shows a clear boundary and rich blood supply, and the diameter of the tumor is generally less than 2 cm\textsuperscript{14}. The nonfunctional pNET presents heterogeneous enhancement, necrosis, and cystic degeneration in enhanced CT images and often has a larger diameter (> 5 cm) than that of the functional pNET. \textsuperscript{68}Ga-DOTATATE PET/CT, the first choice for evaluating well-differentiated histologic subtypes of NETs, provides staging with improved accuracy and additional treatment choices\textsuperscript{20}.

CONCLUSION
Castleman disease rarely occurs in the pancreas. Castleman disease of the pancreas often presents with an abundant blood supply, which, together with the lack of specificity in the clinical presentation, further blurs the distinction of the disease from NETs and PGL. PET/CT is supposed to be selected to guide the typing and subsequent treatment choices for Castleman disease. In our case, PET/CT showed that Castleman disease was solitary in the pancreas, and complete surgical resection led to a good prognosis. In addition to abundant blood supply, high glucose uptake and slightly elevated SSTR expression are potentially new diagnostic features of Castleman disease of the pancreas.

ACKNOWLEDGEMENTS
We are grateful to the patient for providing the information, support, and the written informed consent allowing us to publish their data. We thank Dr Liu (Department of pathology, the Affiliated Hospital of Southwest Medical University) for providing pathological data.

REFERENCES


# ORIGINALITY REPORT

## SIMILARITY INDEX

8%

## PRIMARY SOURCES

<table>
<thead>
<tr>
<th>#</th>
<th>Source URL</th>
<th>Title and Authors</th>
<th>Website</th>
<th>Originality</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>pubs.rsna.org</td>
<td>Yang Wang, Aisheng Dong, Bo Yang, Jianping Lu. &quot;Castleman's Disease of the Kidney Mimicking Renal Cell Carcinoma on FDG PET/CT&quot;, Clinical Nuclear Medicine, 2018</td>
<td>Internet</td>
<td>1%</td>
</tr>
<tr>
<td>4</td>
<td>casesjournal.biomedcentral.com</td>
<td>Yang Wang, Aisheng Dong, Bo Yang, Jianping Lu. &quot;Castleman's Disease of the Kidney Mimicking Renal Cell Carcinoma on FDG PET/CT&quot;, Clinical Nuclear Medicine, 2018</td>
<td>Internet</td>
<td>1%</td>
</tr>
<tr>
<td>5</td>
<td>gs.amegroups.com</td>
<td>Yang Wang, Aisheng Dong, Bo Yang, Jianping Lu. &quot;Castleman's Disease of the Kidney Mimicking Renal Cell Carcinoma on FDG PET/CT&quot;, Clinical Nuclear Medicine, 2018</td>
<td>Internet</td>
<td>1%</td>
</tr>
</tbody>
</table>